MozaffarianDAgarwalMAggarwalMAlexanderLApovianCMBindlishSet alNutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American college of lifestyle medicine, the American society for nutrition, the obesity medicine association, and the obesity society
The SELECT trial result - 20% reduction in major cardiovascular events with weekly semaglutide 2.4mg in adults with established cardiovascular disease plus overweight/obesity - was the first time a weight-loss medication demonstrated cardiovascular outcome benefits in a major randomized controlled trial
This effect is particularly enhanced when used in conjunction with weight loss programs, such as Intermittent Fasting (IF) or regular exercise, yielding even better results
Muscle mass drops
Theres no single formula here: its a conversation based on how youve responded, your other health conditions, and what feels sustainable for you
Recent Findings Obesity is a chronic disease that threatens health across all age groups, particularly children and adolescents